11 Analysts Assess Teva Pharmaceutical Indus: What You Need To Know

Analysts' ratings for Teva Pharmaceutical Indus (NYSE:TEVA) over the last quarter vary from bullish to bearish, as provided by 11 analysts. In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 5 6 0 0 0 Last 30D 1 1 0 0 0 1M Ago 1 0 0 0 0 2M Ago 3 4 0 0 0 3M Ago 0 1 0 0 0 Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $35.36, a high estimate of $40.00, and a low estimate of $28.00. This upward trend is evident, with the current average reflecting a 17.01% increase from the previous average price target of $30.22. Diving into Analyst Ratings: An In-Depth Exploration A clear picture of Teva Pharmaceutical Indus's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets. Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target Louise Chen Scotiabank Raises Sector Outperform $40.00 $35.00 Les Sulewski Truist Securities Raises Buy $38.00 $36.00 Glen Santangelo Jefferies Raises Buy $40.00 $29.00 David Amsellem Piper Sandler Raises Overweight $40.00 $30.00 Matt Dellatorre Goldman Sachs Raises Buy $35.00 $31.00 Chris Schott JP Morgan Raises Overweight $35.00 $28.00 Jason Gerberry B of A Securities Raises Buy $32.00 $29.00 Glen Santangelo Barclays Announces Overweight $35.00 - Matt Dellatorre Goldman Sachs Raises Buy $31.00 $28.00 Louise Chen Scotiabank Announces Sector Outperform $35.00 - Chris Schott JP Morgan Raises Overweight $28.00 $26.00 Key Insights: Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Teva Pharmaceutical Indus. This information offers a snapshot of how analysts perceive the current state of the company. Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Teva Pharmaceutical Indus compared to the broader market. Price Targets: Analysts predict movements in price targets, offering estimates for Teva Pharmaceutical Indus's future value. Examining the current and prior targets offers insights into analysts' evolving expectations. Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Teva Pharmaceutical Indus's market standing. Stay informed and make data-driven decisions with our Ratings Table. Stay up to date on Teva Pharmaceutical Indus analyst ratings. Discovering Teva Pharmaceutical Indus: A Closer Look Teva Pharmaceutical, based in Israel, is the leading generic drug manufacturer in the world. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in three main therapeutic areas: the central nervous system with Copaxone, Ajovy, and Austedo; respiratory with Qvar and ProAir; and oncology with Truxima, Herzuma, and Bendeka/Treanda. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor. Teva Pharmaceutical Indus's Financial Performance Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity. Revenue Growth: Teva Pharmaceutical Indus's remarkable performance in 3M is evident. As of 30 September, 2025, the company achieved an impressive revenue growth rate of 3.42%. This signifies a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector. Net Margin: Teva Pharmaceutical Indus's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of 9.67%, the company may encounter challenges in effective cost control. Return on Equity (ROE): Teva Pharmaceutical Indus's ROE stands out, surpassing industry averages. With an impressive ROE of 6.15%, the company demonstrates effective use of equity capital and strong financial performance. Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of 1.08%, the company may need to address challenges in generating satisfactory returns from its assets. Debt Management: Teva Pharmaceutical Indus's debt-to-equity ratio stands notably higher than the industry average, reaching 2.35. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage. Understanding the Relevance of Analyst Ratings Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability. This article was generated by Benzinga's automated content engine and reviewed by an editor.